This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non–Small-Cell Lung Cancer: The Bar Is Dropping
This study evaluated over 200 RTCs of systemic therapy for NSCLC. There has been a steady increase in the number of trials reporting outcomes for progression-free survival. Over 50% of trials now report a positive outcome without meeting the primary endpoint of the trial. Although the sample size of the trials is increasing, the magnitude of reported survival gain is decreasing (now 2.5 mos).